We are advancing a pipeline of AlloCAR TTM candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Our AlloCAR T portfolio includes rights to 15 preclinical CAR T cell therapy targets licensed from Cellectis and U.S. rights to clinical candidates ALLO-501 and UCART19 licensed from Servier, currently in Phase 1 development for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) and relapsed/refractory acute lymphoblastic leukemia (ALL), respectively.
1 Phase 3 may not be required if Phase 2 is registrational
2 Servier will hold ex-US commercial rights. Servier is the sponsor of the UCART19 trials
3 Allogene is the sponsor of the ALLO-501 trial and expected sponsor of the ALLO-501A trial
4 ALLO-647 intended to enable expansion and persistence of allogeneic CAR T product candidates
5 Allogene sponsored trial in combination with SpringWorks Therapeutics; Initiation expected 2H 2020